Ocular Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA OKs Vyzulta for Glaucoma, Ocular Hypertension - Medscape



Medscape
 
FDA OKs Vyzulta for Glaucoma, Ocular Hypertension 
Medscape
The US Food and Drug Administration (FDA) has approved latanoprostene bunod ophthalmic solution 0.024% (Vyzulta, Bausch & Lomb/Nicox SA) for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

 


FDA Okays Treatment For Patients With Glaucoma Or Ocular Hypertension - Pharmaceutical Processing



Pharmaceutical Processing
 
FDA Okays Treatment For Patients With Glaucoma Or Ocular Hypertension 
Pharmaceutical Processing
Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, a global eye health company, and Nicox S.A., an international ophthalmic company, last week announced that the U.S. Food and Drug Administration (FDA) has approved ...

 


FDA Approves Vyzulta for Glaucoma, Ocular Hypertension - Managed Care magazine



FiercePharma
 
FDA Approves Vyzulta for Glaucoma, Ocular Hypertension 
Managed Care magazine
The FDA has approved latanoprostene bunod ophthalmic solution, 0.024% (Vyzulta, Bausch + Lomb) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Vyzulta, a once-daily monotherapy, is the first ...
Vyzulta Approved to Treat Patients With Open-Angle Glaucoma, Ocular HTN Monthly Prescribing Reference
Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline ... GlobeNewswire (press release)
FDA approves Bausch + Lomb glaucoma drop Healio
Nasdaq  -FiercePharma  -TheStreet.com 
all 16 news articles » 


Ocular Hypertension Market Pipeline Review H2- Companies Involved in Therapeutics Development - MilTech



Ocular Hypertension Market Pipeline Review H2- Companies Involved in Therapeutics Development 
MilTech
Ocular Hypertension Market? Pipeline Review, H2 analysis report speaks about key players with pipeline review and targeted therapeutics covering drugs profile, Symptoms and Treatment includes of Ocular Hypertension industry. The report also covers ...

and more » 


Tonomonitor©: A Device For Detecting Ocular Hypertension With Self-Testing Capability - Med Device Online (press release)



Tonomonitor©: A Device For Detecting Ocular Hypertension With Self-Testing Capability 
Med Device Online (press release)
Dr. Michael Lawrence Cohen, has been granted a U.S. patent for the Tonomonitor, an intraocular pressure monitoring device. The light, handheld biomechanical device is unique in design, cost, function, portability, and ease of use. Because the ...

 


Ocular Therapeutix (NASDAQ:OCUL) and Its Rivals Head-To-Head Comparison - The Ledger Gazette



Ocular Therapeutix (NASDAQ:OCUL) and Its Rivals Head-To-Head Comparison 
The Ledger Gazette
OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ...
IDEX (IEX) Reaches $130.05 52-Week High; 6 Analysts Are Bullish Ocular Therapeutix (OCUL) Last Week NormanObserver.com

all 16 news articles » 


Netarsudil ophthalmic solution trial begins in Japan - Healio



Netarsudil ophthalmic solution trial begins in Japan 
Healio
Patients with open-angle glaucoma patients in the study will have baseline IOP of 15 mm Hg to less than 35 mm Hg, while patients with ocular hypertension will have IOP greater than 22 mm Hg to less than 35 mm Hg, the release said. ?Studies in Japan ...

 


Bimatoprost: Good Option for IOP Reduction in Nonresponders - Medscape



Medscape
 
Bimatoprost: Good Option for IOP Reduction in Nonresponders 
Medscape
The aim of this study was to determine whether a switch to bimatoprost 0.03% monotherapy in nonresponding patients with glaucoma or ocular hypertension provides additional intraocular pressure (IOP) reduction. Fifty-nine consecutive patients were ...

 


Contrasting Ocular Therapeutix (NASDAQ:OCUL) & Its Peers ... - Dispatch Tribunal



Contrasting Ocular Therapeutix (NASDAQ:OCUL) & Its Peers ... 
Dispatch Tribunal
Ocular Therapeutix (NASDAQ: OCUL) is one of 79 publicly-traded companies in the ?Medical Equipment, Supplies & Distribution? industry, but how does it weigh ...
Timucuan Asset Management Has Increased By $1.08 Million Its Hexcel (HXL) Position; Ocular Therapeutix (OCUL ... Key Gazette

all 3 news articles » 


Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... - Business Wire (press release)



Wolcott Daily
 
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... 
Business Wire (press release)
Aerie's two current product candidates are once-daily intraocular pressure lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA (New Drug Application) for Rhopressa? (netarsudil ophthalmic ...
7 Stocks of the Month: December Edition Zacks.com
Aerie Pharmaceuticals, Inc. - AERI - Stock Price Today - Zacks Zacks Investment Research

all 40 news articles »